Lysosomal Disorders

Review top news and interview highlights from the week ending January 28, 2022.

The latest hold on MB-207 follows a similar hold on another XSCID therapy, MB-107.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

Investigators from IRCCS San Raffaele analyzed results from a phase 1/2 study on atidarsagene autotemcel.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

Eli-cel remains on clinical hold in cerebral adrenoleukodystrophy after a report of persistent anemia.

The first patient with Fabry disease dosed with FLT190 2 years ago continues to have elevated, sustained α-Gal A.

Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the phase 2 FREEDOM-3 trial and preclinical studies of the cell therapy FCR-001.

Many cell and gene therapy companies are initiating new programs and collaborations with the start of the new year.

The reprioritization comes as the SIG-001 program remains on clinical hold after scarred and inviable cell spheres were observed in a treated patient.

Review top news and interview highlights from the week ending January 7, 2022.

AVRIOBIO announced that it is shifting priorities to focus on their gene therapy programs in Gaucher disease.

The DSMB has recommended that enrollment expand and doses be escalated from 3.3 to 5 mg in 1 cohort of the KIK-AS study.

Ralph Laufer, PhD, chief scientific officer, Lysogene, discussed gene therapy programs in GM1 gangliosidosis and Fragile X syndrome.

The phase 3 GEM-3 study met both its primary and secondary end points compared with placebo in dEB.

Review some of our most-viewed coverage of advancements in cell therapies, including the latest study results and insights from experts in the field.

Review top news and interview highlights from the week ending December 17, 2021.

Review top news and interview highlights from the week ending December 9, 2021.

Ralph Laufer, PhD, chief scientific officer, Lysogene, discussed LYS-SAF302, its mechanism of action, trial data, and further research.

Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.

Review top news and interview highlights from the week ending November 26, 2021.

The chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.

The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s ex-vivo and in-vivo gene therapy platforms.

Review top news and interview highlights from the week ending November 19, 2021.

The gene-edited approach hopes to overcome with the shortcomings of autologous hematopoietic stem-cell transplantation.